Thanks to its recent acquisition by Merck on behalf of its planned spinoff of Organon, Alydia Health, a Fogarty Innovation graduate, is one step closer to its goal of eradicating postpartum hemorrhage (PPH), the leading global cause of maternal death. The deal is...
Securing financial backing is always a hot topic for startups, and never more so than today, when COVID-19 has upset the traditional landscape. That was the topic of “Medtech Innovation: The Post-COVID World of Innovation,” at the recent Transcatheter...
It’s always encouraging to hear about medtech entrepreneurs finding success. But have you ever wondered how they got there? The road, as you’d assume, is not straight, as nearly 100 FDA participants heard from successful entrepreneurs at an engaging, educational panel...
COVID-19 might have temporarily closed dentist offices, but that hasn’t stopped iDentical from raising a healthy amount of cash for its innovative alternative to traditional dental implants. Fogarty Institute company-in-residence iDentical has developed drill-free,...
Most successful professionals will agree that if there is a “secret to success,” it’s having a mentor. And that holds true for the medtech profession as well, judging by the results of our Diversity by Doing (DxD) HealthTech survey. As noted in our recent report, both...
It has been an action-packed 12 months for EnSpectra Health, a Fogarty Institute company that is leading a digital transformation in skin cancer pathology. While 2019 brought a number of notable developments, most recently EnSpectra received a $2 million grant that...
Imagine going to the doctor’s office for your annual check-up. The nurse starts going through the usual tests, such as measuring your blood pressure, heart rate and temperature and completing the blood draw from your arm. Then the nurse immediately starts testing your...
Fogarty Institute graduate Alydia Health, formerly known as InPress Technologies, is well on its way to conducting a pivotal study, thanks to the closing of a recent $10M Series B round led by Global Health Investment Fund. The U.S. study aims to prove the safety and...
As the first and only device cleared by the FDA to collect cells from the fallopian tubes, the Mako 7 device, originally developed by nVision, a Fogarty Institute graduate, offers a potential platform for earlier detection of ovarian cancer. The company was recently...
"There is a better way" is a common mantra heard frequently in discussions between Fogarty Institute mentors and its entrepreneurs. It's what drives us each day to devise and create new technologies that will transform patient care. And while the process is not always...